Carregant...
Some Effects of CB1 Antagonists with Inverse Agonist and Neutral Biochemical Properties,
The CB1 inverse agonist/antagonist SR141716A recently has been introduced for the management of obesity (rimonabant; Acomplia) and appears to have beneficial effects. However, its utility may be hampered in some individuals by adverse effects including nausea or emesis or by mood depression. The rec...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2007
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2441972/ https://ncbi.nlm.nih.gov/pubmed/18076956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.physbeh.2007.11.007 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|